Inactive Instrument
Norda ASA Stock Oslo Bors
Stocks
NORD
NO0010285190
Biotechnology & Medical Research
| Market Cap | 513M 53.02M 46.47M 42.95M 39.5M 74.54M 5.11B 75.73M 514M 201M 2.5B 199M 195M 8.62B | P/E 2023 * |
-
| P/E 2024 | 3.26x |
|---|---|---|---|---|---|
| Enterprise Value | 264M 27.31M 23.94M 22.13M 20.35M 38.4M 2.63B 39.01M 265M 104M 1.29B 103M 100M 4.44B | EV / Sales 2023 |
-1.24x | EV / Sales 2024 | 0.4x |
| Free-Float |
6.26% | Yield 2023 * |
-
| Yield 2024 | 32.5% |
| 04-09 | Exercise of Warrants by primary insiders | AQ |
| 25-07-10 | Mandatory Notification of Trade | AQ |
| 25-06-04 | Ocean Sun: Mandatory notification of trade | AQ |
| 25-03-27 | Nykode Therapeutics - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider | AQ |
| 25-03-03 | Notification of trade | AQ |
| 1 day | +3.37% |
| Manager | Title | Age | Since |
|---|---|---|---|
Frode Westvold
CEO | Chief Executive Officer | - | 2013-04-07 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 2014-01-30 | |
| Director/Board Member | 68 | 2013-06-19 | |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.37% | -6.12% | - | - | 46M | ||
| -0.49% | -4.01% | -0.84% | +2.28% | 49.18B | ||
| -3.10% | -1.94% | +370.99% | +572.60% | 39.58B | ||
| -0.46% | +2.18% | +5.44% | +61.01% | 34.69B | ||
| -1.14% | -1.76% | +26.94% | -9.93% | 34.42B | ||
| -1.82% | -1.43% | +0.52% | +31.85% | 27.11B | ||
| -3.54% | -5.08% | - | - | 16.21B | ||
| -1.82% | -0.43% | +69.28% | +113.82% | 15.36B | ||
| +1.17% | +2.30% | +15.87% | +18.26% | 14.05B | ||
| -2.25% | +0.05% | +15.77% | -32.83% | 13.02B | ||
| Average | -1.01% | -0.85% | +63.00% | +94.63% | 27.07B | |
| Weighted average by Cap. | -1.43% | -1.02% | +75.91% | +118.68% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 86.92M 8.98M 7.87M 7.28M 6.69M 12.63M 866M 12.83M 86.99M 34.1M 424M 33.72M 32.98M 1.46B | 372M 38.42M 33.67M 31.12M 28.63M 54.01M 3.7B 54.88M 372M 146M 1.81B 144M 141M 6.24B |
| Net income | 31.17M 3.22M 2.82M 2.61M 2.4M 4.53M 311M 4.6M 31.2M 12.23M 152M 12.09M 11.83M 524M | 126M 13.01M 11.4M 10.54M 9.7M 18.29M 1.25B 18.59M 126M 49.41M 614M 48.86M 47.79M 2.12B |
| Net Debt | -311M -32.15M -28.18M -26.05M -23.96M -45.21M -3.1B -45.93M -312M -122M -1.52B -121M -118M -5.23B | -249M -25.71M -22.53M -20.83M -19.15M -36.14M -2.48B -36.72M -249M -97.62M -1.21B -96.52M -94.42M -4.18B |
Employees
-
















